Ari Maizel - 21 Jan 2026 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Signature
/s/ Ari Maizel
Issuer symbol
AXSM
Transactions as of
21 Jan 2026
Net transactions value
-$852,825
Form type
4
Filing time
23 Jan 2026, 19:00:03 UTC
Previous filing
25 Feb 2025
Next filing
27 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Maizel Ari Chief Commercial Officer C/O AXSOME THERAPEUTICS, INC., ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK /s/ Ari Maizel 23 Jan 2026 0002042289

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Options Exercise $530,475 +7,500 $70.73 7,500 21 Jan 2026 Direct F1
transaction AXSM Common Stock Sale $1,383,300 -7,500 -100% $184.44 0 21 Jan 2026 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -7,500 -19% $0.000000 31,210 21 Jan 2026 Common Stock 7,500 $70.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F2 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F3 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $183.70 and $184.81.